Skip Nav Destination
Issues
15 April 2015
-
Cover Image
Cover Image
The cover depicts nuclear fluorescence of a three-dimensional organotypic epithelial raft section generated from head and neck squamous cell carcinoma cells. The cells were derived from a patient with Fanconi anemia (FA) and corrected to achieve FA pathway competency. For details, see the article by Lombardi and colleagues on page 1962 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
20th Anniversary Commentary
CCR Translations
Molecular Pathways
CCR Focus
Cancer Therapy: Clinical
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Bastian von Tresckow; Franck Morschhauser; Vincent Ribrag; Max S. Topp; Caly Chien; Shobha Seetharam; Regina Aquino; Sonja Kotoulek; Carla J. de Boer; Andreas Engert
Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy
Yen-Shen Lu; for the Taiwan Breast Cancer Consortium; Tom Wei-Wu Chen; for the Taiwan Breast Cancer Consortium; Ching-Hung Lin; for the Taiwan Breast Cancer Consortium; Dah-Cherng Yeh; for the Taiwan Breast Cancer Consortium; Ling-Ming Tseng; for the Taiwan Breast Cancer Consortium; Pei-Fang Wu; for the Taiwan Breast Cancer Consortium; Kun-Ming Rau; for the Taiwan Breast Cancer Consortium; Bang-Bin Chen; for the Taiwan Breast Cancer Consortium; Ta-Chung Chao; for the Taiwan Breast Cancer Consortium; Shu-Min Huang; for the Taiwan Breast Cancer Consortium; Chiun-Sheng Huang; for the Taiwan Breast Cancer Consortium; Tiffany Ting-Fang Shih; for the Taiwan Breast Cancer Consortium; Ann-Lii Cheng; for the Taiwan Breast Cancer Consortium
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer
Taofeek K. Owonikoko; Suresh S. Ramalingam; Daniel L. Miller; Seth D. Force; Gabriel L. Sica; Jennifer Mendel; Zhengjia Chen; Andre Rogatko; Mourad Tighiouart; R. Donald Harvey; Sungjin Kim; Nabil F. Saba; Allan Pickens; Madhusmita Behera; Robert W. Fu; Michael R. Rossi; William F. Auffermann; William E. Torres; Rabih Bechara; Xingming Deng; Shi-Yong Sun; Haian Fu; Anthony A. Gal; Fadlo R. Khuri
Author Choice
Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials
Saeed Rafii; Desamparados Roda; Elena Geuna; Begona Jimenez; Karim Rihawi; Marta Capelan; Timothy A. Yap; L. Rhoda Molife; Stanley B. Kaye; Johann S. de Bono; Udai Banerji
Author Choice
First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer
Geoffrey I. Shapiro; Katherine M. Bell-McGuinn; Julian R. Molina; Johanna Bendell; James Spicer; Eunice L. Kwak; Susan S. Pandya; Robert Millham; Gary Borzillo; Kristen J. Pierce; Lixin Han; Brett E. Houk; Jorge D. Gallo; Maria Alsina; Irene Braña; Josep Tabernero
Author Choice
Bevacizumab in Patients with Nonsquamous Non–Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study
Benjamin Besse; Sylvestre Le Moulec; Julien Mazières; Hélène Senellart; Fabrice Barlesi; Christos Chouaid; Eric Dansin; Henri Bérard; Lionel Falchero; Radj Gervais; Gilles Robinet; Anne-Marie Ruppert; Roland Schott; Hervé Léna; Christelle Clément-Duchêne; Xavier Quantin; Pierre Jean Souquet; Jean Trédaniel; Denis Moro-Sibilot; Maurice Pérol; Anne-Catherine Madroszyk; Jean-Charles Soria
Personalized Medicine and Imaging
Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers
André Oberthuer; Dilafruz Juraeva; Barbara Hero; Ruth Volland; Carolina Sterz; Rene Schmidt; Andreas Faldum; Yvonne Kahlert; Anne Engesser; Shahab Asgharzadeh; Robert Seeger; Miki Ohira; Akira Nakagawara; Paola Scaruffi; Gian Paolo Tonini; Isabelle Janoueix-Lerosey; Olivier Delattre; Gudrun Schleiermacher; Jo Vandesompele; Frank Speleman; Rosa Noguera; Marta Piqueras; Jean Bénard; Alexander Valent; Smadar Avigad; Isaac Yaniv; Richard G. Grundy; Monika Ortmann; Chunxuan Shao; Manfred Schwab; Roland Eils; Thorsten Simon; Jessica Theissen; Frank Berthold; Frank Westermann; Benedikt Brors; Matthias Fischer
Cancer Therapy: Preclinical
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood–Brain Barrier in Glioblastoma
Jenny L. Pokorny; David Calligaris; Shiv K. Gupta; Dennis O. Iyekegbe, Jr; Dustin Mueller; Katrina K. Bakken; Brett L. Carlson; Mark A. Schroeder; Debra L. Evans; Zhenkun Lou; Paul A. Decker; Jeanette E. Eckel-Passow; Vincenzo Pucci; Bennett Ma; Stuart D. Shumway; William F. Elmquist; Nathalie Y.R. Agar; Jann N. Sarkaria
Author Choice
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer
Liang Zhang; Xiaoen Wang; Andrea J. Bullock; Marcella Callea; Harleen Shah; Jiaxi Song; Kelli Moreno; Barbara Visentin; Douglas Deutschman; David C. Alsop; Michael B. Atkins; James W. Mier; Sabina Signoretti; Manoj Bhasin; Roger A. Sabbadini; Rupal S. Bhatt
Biology of Human Tumors
Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis
Marco Dal Molin; Ming Zhang; Roeland F. de Wilde; Niki A. Ottenhof; Neda Rezaee; Christopher L. Wolfgang; Amanda Blackford; Bert Vogelstein; Kenneth W. Kinzler; Nickolas Papadopoulos; Ralph H. Hruban; Anirban Maitra; Laura D. Wood
Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers
Anne J. Lombardi; Elizabeth E. Hoskins; Grant D. Foglesong; Kathryn A. Wikenheiser-Brokamp; Lisa Wiesmüller; Helmut Hanenberg; Paul R. Andreassen; Allison J. Jacobs; Susan B. Olson; Winifred W. Keeble; Laura E. Hays; Susanne I. Wells
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.